Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ApnimedAPMD +13.64%8 EBITDA Margin % is 80.23% as of Mar. 2026. GuruFocus rates APMD with a GF Score™ of 8/100. Among 942 Biotechnology companies, Apnimed ranks worse than 106157.01% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Apnimed's EBITDA for the
three
months ended in Mar. 2026 was $68.05 Mil. Apnimed's Revenue for the
three
months ended in Mar. 2026 was $84.81 Mil. Therefore, Apnimed's EBITDA margin for the quarter that ended in Mar. 2026 was 80.23%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Apnimed EBITDA Margin % Related Terms
Apnimed EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Apnimed's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apnimed EBITDA Margin % Chart
Apnimed Annual Data
Trend
Dec24
Dec25
EBITDA Margin %
-1,425.50
-139.84
Apnimed Quarterly Data
Dec24
Mar25
Dec25
Mar26
EBITDA Margin %
0.00
-865.70
0.00
80.23
APMD vs : EBITDA Margin % Comparison
For the Biotechnology subindustry, Apnimed's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apnimed EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apnimed's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Apnimed's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apnimed (APMD) has a EBITDA Margin % of 80.23% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Apnimed and its competitors. According to the industry distribution chart, Apnimed ranks #999999 out of 942 companies in the Biotechnology industry.
Is Apnimed's EBITDA Margin % too high?
Apnimed's current EBITDA Margin % is 80.23%. Based on the distribution chart, Apnimed ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Apnimed has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Apnimed's EBITDA Margin % compare to ?
According to the Biotechnology industry distribution chart, Apnimed ranks #999999 out of 942 companies for EBITDA Margin %. This places Apnimed in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Apnimed and its competitors. Apnimed's current EBITDA Margin % is 80.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apnimed stock overvalued right now?
Apnimed (APMD) has a current EBITDA Margin % of 80.23%. The current EBITDA Margin % is 80.23%. Apnimed's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Apnimed (APMD), the current EBITDA Margin % is 80.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
8GF Score
Get the complete analysis for APMD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APMD has been successfully added to your 
